Treatment: PrEP (HIV pre-exposure prophylaxis)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Initial tests (before starting PrEP)
Laboratory tests
- HIV serology
- Hepatitis B serology (HBsAg, anti-HBc antibodies, anti-HBs antibodies)
- Hepatitis A serologyif neededImmune status unknown, with a view to vaccination against hepatitis A (MSM in particular).
- Hepatitis C serology
- Syphilis serology
- ALT
- Serum creatinine with eGFR
- β-hCGif neededWoman without contraception.
- Neisseria gonorrhoeae and Chlamydia trachomatis NAAT (PCR) on 3 sites (pharyngeal, anal, urinary or vaginal), depending on practices
Do not order
Follow-up tests (month 1, then every 3 to 6 months)
Laboratory tests
- Serum creatinine with eGFR
- HIV serology
- ALT
- Syphilis serologyif neededAccording to exposure: every 3 to 4 months in MSM who have had several partners in the quarter; at least every 6 months in people with low exposure.
- Neisseria gonorrhoeae and Chlamydia trachomatis NAAT (PCR) on 3 sites (pharyngeal, anal, urinary or vaginal), depending on practicesif neededAccording to exposure: every 3 to 4 months in MSM who have had several partners in the quarter; at least every 6 months in people with low exposure.
- Hepatitis C serologyif neededTraumatic anal intercourse, nasal or injected drug use (HCV RNA if previous serology positive).
Do not order
Annual tests
Laboratory tests
- Hepatitis C serologyif neededAnnual according to HAS 2021; HAS 2024 reserves monitoring for traumatic anal intercourse and nasal or injected drug use.
- HIV serology
- Syphilis serologyif neededAccording to exposure (every 3 to 4 months in MSM with multiple partners; at least every 6 months otherwise).
- Hepatitis B serologyif neededPerson not immune at the initial work-up, if vaccination has not been done: the priority is to vaccinate; neither HAS 2021 nor HAS 2024 provides for annual hepatitis B serology.
- Neisseria gonorrhoeae and Chlamydia trachomatis NAAT (PCR) on 3 sites (pharyngeal, anal, urinary or vaginal), depending on practices
Urine tests
- Urine protein:creatinine ratio (spot sample)
Sources (8)
- EPI-PHARE (GIS ANSM-CNAM). Suivi de l'utilisation de Truvada® ou génériques pour une prophylaxie pré-exposition (PrEP) au VIH à partir du SNDS : actualisation des données jusqu'au 30 juin 2025. Rapport, 27 novembre 2025.
- Haute Autorité de santé. Traitement préventif pré-exposition de l'infection par le VIH. Fiche synthèse, juillet 2024.
- Haute Autorité de santé (avec ANRS-MIE et CNS). Traitement préventif pré-exposition de l'infection par le VIH. Recommandation de bonne pratique, juillet 2024.
- Réponses rapides dans le cadre de la COVID-19 - Prophylaxie (PrEP) du VIH par ténofovir disoproxil / emtricitabine dans le cadre de l’urgence sanitaire
- Brady M, Clutterbuck D, Rodger A, et al. British Association for Sexual Health and HIV/British HIV Association guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2025. BASHH/BHIVA (Royaume-Uni), juillet 2025.
- US Preventive Services Task Force. Prevention of Acquisition of HIV: Preexposure Prophylaxis. Final Recommendation Statement, 22 août 2023 (grade A).
- Organisation mondiale de la santé. Differentiated and simplified pre-exposure prophylaxis for HIV prevention: update to WHO implementation guidance. Technical brief. Genève : OMS, 2022 (ISBN 978-92-4-005369-4).
- Garvey L, Bhagani S, Kulasegaram R, et al. British Association for Sexual Health and HIV (BASHH) guidelines on the management of viral hepatitis 2026. Int J STD AIDS. 2026 (publication en ligne).